Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...

On readmission, in January, 1965, no new physical findings were evident, and it was not known whether the zinc glucagon was inactive or the worsening condition was due to progression of the disease.

GLP-1 receptor agonists may increase the risk of several autoimmune diseases in adults with type 2 diabetes, according to ...

Glucagon receptors, found in hepatocytes and renal cells, may provide further advantages, perhaps lowering the incidence of metabolic liver diseases and diabetic kidney disease.

India’s drug regulator has approved Eli Lilly and Company’s diabetes and obesity drug Mounjaro in a KwikPen presentation, the ...

Article Title. Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective ...